Related Experiment Videos
[Implanted percutaneous continuous hepatic arterial infusion system for nonresectable liver metastasis]
1Department of Radiology, Third Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou 510630, China.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|February 28, 2002
Summary
Continuous hepatic arterial infusion of 5-fluorouracil (5-Fu)/calcium folinate (CF) improved survival in patients with unresectable liver metastasis. This treatment demonstrated a 47.1% response rate and mild side effects, offering a viable therapeutic option.
Area of Science:
- Oncology
- Hepatology
- Interventional Radiology
Context:
- Liver metastasis presents a significant challenge in managing unresectable cancer.
- Percutaneous arterial infusion systems offer targeted drug delivery.
- Optimizing treatment for nonresectable liver tumors is crucial for patient outcomes.
Purpose:
- To assess the efficacy of continuous hepatic arterial infusion of 5-fluorouracil (5-Fu) and calcium folinate (CF) using an implanted drug delivery system.
- To evaluate treatment response, survival rates, and toxicity in patients with nonresectable liver metastasis.
Summary:
- A study involving 68 patients with nonresectable liver metastasis utilized continuous hepatic arterial infusion of 5-Fu/CF and dexamethasone via a percutaneously implanted drug delivery system.
- The overall response rate was 47.1%, with a median survival of 15.2 months. Response correlated with tumor burden and was better for gastrointestinal tract cancers.
- Treatment resulted in mild toxicity, suggesting a favorable safety profile.
Impact:
- Continuous hepatic arterial infusion of 5-Fu/CF demonstrates potential for prolonging survival in patients with nonresectable liver metastasis.
- This approach may improve the quality of life for patients with advanced liver disease.
- The findings support the use of targeted intra-arterial chemotherapy as a treatment strategy.